Related Experiment Video

Updated: Aug 12, 2026

Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection
08:52

Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection

Published on: February 17, 2015

The sinus node inhibitor UL-FS 49 lacks significant inotropic effect

Z Y Chen1, B K Slinker

  • 1Department of Medicine, University of Vermont, Burlington.

Journal of Cardiovascular Pharmacology
|February 1, 1992
PubMed

Insights

UL-FS 49, a sinus node inhibitor, has minimal physiological impact on left ventricular function. This study found no significant direct effects, suggesting it is not a potent inotropic agent.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • UL-FS 49 is a sinus node inhibitor investigated for potential benefits in myocardial oxygen balance.
  • Previous research on UL-FS 49's inotropic effects yielded inconsistent results across different experimental models.

Purpose of the Study:

  • To definitively assess the independent inotropic effect of UL-FS 49 on left ventricular function.
  • To clarify the physiological significance of UL-FS 49's impact on cardiac hemodynamics.

Main Methods:

  • Hemodynamic responses were measured under both steady-state conditions and during random preload/afterload alterations.
  • Multiple linear regression modeling was employed to analyze transient hemodynamic sequences.

Main Results:

  • Under steady-state conditions, UL-FS 49 showed a minor, likely insignificant, increase in stroke volume (3%) and peak positive dP/dt (7%).
  • No statistically significant changes were observed in end-diastolic pressure, end-diastolic volume, peak systolic pressure, end-systolic pressure, or heart rate.
  • Advanced analysis of transient responses confirmed UL-FS 49 lacks a significant direct effect on left ventricular function.

Conclusions:

  • UL-FS 49 does not exert a physiologically important direct effect on left ventricular pump function.
  • The study concludes that UL-FS 49 is not a significant inotropic agent.

More Related Videos

Methods for the Isolation, Culture, and Functional Characterization of Sinoatrial Node Myocytes from Adult Mice09:32

Methods for the Isolation, Culture, and Functional Characterization of Sinoatrial Node Myocytes from Adult Mice

Published on: October 23, 2016

High-resolution Optical Mapping of the Mouse Sino-atrial Node11:07

High-resolution Optical Mapping of the Mouse Sino-atrial Node

Published on: December 2, 2016

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...